Trials / Completed
CompletedNCT03774771
Safety, Pharmacokinetics, and Clinical Effects of Cinacalcet (AMG 073) in Primary Hyperparathyroidism
A Randomized, Double-Blind, Placebo-Controlled, Multicenter, 6-week Dose-Ranging Study to Assess the Safety, Pharmacokinetics, and Clinical Effects of an Oral Calcimimetic Agent (AMG 073) in Primary Hyperparathyroidism
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 48 (actual)
- Sponsor
- Amgen · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective was to assess the safety and tolerability of cinacalcet in adults with primary hyperparathyroidism (HPT) when administered as a single oral once daily doses for 6 consecutive weeks and twice daily for 15 consecutive days.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Cinacalcet | Capsule for oral administration |
| DRUG | Placebo | Capsules for oral administration |
Timeline
- Start date
- 1998-09-29
- Primary completion
- 1999-12-13
- Completion
- 1999-12-13
- First posted
- 2018-12-13
- Last updated
- 2018-12-13
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03774771. Inclusion in this directory is not an endorsement.